

Accepted Article

PREVALENCE AND RISK FACTORS FOR MAJOR INFECTIONS IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. INFLUENCE ON THE DISEASE OUTCOME.

Eloi Garcia-Vives¹, Alfons Segarra-Medrano², Ferran Martinez-Valle¹, Irene Agraz², Roser Solans-Laque¹.

¹Autoimmune Systemic Diseases Unit, Internal Medicine Department; ²Nephrology Department. Vall d'Hebron University Hospital. Barcelona, Spain.

Eloi Garcia-Vives and Roser Solans-Laque declare that both have equally contributed to the paper elaboration.

The authors declare no conflicts of interest.

Corresponding author: rsolans@vhebron.net

Keywords: ANCA, Vasculitis, Infections, Survival.

This article has been accepted for publication in The Journal of Rheumatology following full peer review. This version has not gone through proper copyediting, proofreading and typesetting, and therefore will not be identical to the final published version. Reprints and permissions are not available for this version. Please cite this article as doi 10.3899/jrheum.190065. This accepted article is protected by copyright. All rights reserved.

ABSTRACT:

Objective: to analyse the role that infections play on the ANCA-associated vasculitis outcome.

Methods: retrospective study of adult patients with AAV diagnosed in a tertiary centre. Clinical features, laboratory findings, treatment, relapses, major infections and outcome were evaluated.

Results: 132 patients (51 MPA, 52 GPA, 29 EGPA) with a mean follow-up of 140 (96-228) months were included. ANCAs were positive in 85% of cases. A total of 300 major infections, mainly bacterial (87%), occurred in 60% patients during the follow-up. Lower respiratory tract (64%) and urinary tract infections (11%) were the most frequent, followed by bacteraemia (9%). A total of 7.4% opportunistic infections were observed, most due to systemic mycosis. Up to 46% of all opportunistic infections took place in the first year of diagnosis, and 55% of them under CYC treatment. Bacterial infections were associated with BVASv.3>15 at the disease onset (OR 2.35, 95%CI 1.14-4.76, p=0.021), a total cumulative CYC dose >8.65gr (OR 2.67, 95%CI 1.15-4.82, p=0.008), dialysis (OR 3.07, 95%CI 1.07-8.79, p=0.04) and development of leukopenia during the follow-up (OR 2.63, 95%CI 1.23-5.64, p=0.016). Leukopenia was the only factor independently related to opportunistic infections (OR 4.31, 95%CI 1.43-12.98, p=0.006). Forty-four patients died: 25 with MPA, 11 with GPA and 8 with EGPA. Death was due to infection in 50% of cases, directly (34%) or associated to active disease (16%). Patients who suffered from major infections had an increased mortality from any cause.

Conclusion: Our results confirm that major infections are the main cause of death in patients with AAV.

INTRODUCTION

ANCA-associated vasculitides (AAV) are systemic diseases characterized by the presence of necrotizing inflammation predominantly involving small-size vessels in conjunction with serum antineutrophil cytoplasmic antibodies (ANCA) in most cases. Three different entities are distinguished: granulomatosis with polyangiitis (GPA) formerly known as Wegener's, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA) classically known as Churg-Strauss syndrome (1). GPA typically affects the upper and lower respiratory tract and kidneys; MPA is characterized by severe renal affection usually due to pauci-immune necrotizing glomerulonephritis, and EGPA is characterized by asthma, hypereosinophilia and nasal polyposis (2).

Historically, patients with untreated AAV died early due to the severity of the disease, with mortality a rate of 80-90% in the first year (3,4), except for EGPA that showed higher survival rates (5). The introduction of corticosteroids (CS) and cyclophosphamide (CYC) therapy, clearly improved the rate of survival but with a high toxicity (6). Several randomized trials allowed tailoring the treatment according to the clinical disease severity, but the mortality rate remains still high, with fulminant complications (7). While in the past patients tended to die early due to uncontrolled disease, nowadays treatment related toxicity plays a central role in mortality (8). Several studies have analysed the prognostic factors associated with AAV mortality, reporting infections as one of the most important aetiologies, representing up to 66% during the first 12 months (8–10).

The aim of the present study was to analyse the prevalence and risk factors of major infections among patients with AAV and its influence on the disease outcome.

METHODS

This was a retrospective, single-centre study. Adult patients (>18years) diagnosed as having AAV between January 1990 and January 2016 at the Autoimmune & Systemic Diseases Unit of the Internal Medicine Department and the Nephrology Department of a tertiary Centre were evaluated. The median follow-up was 140 (96-228) months. Patients were classified according to the Chapel-Hill 2012 revised criteria (1). The following data were collected from clinical files: demographic features, clinical manifestations and main laboratory findings at the time of diagnosis (white blood count (WBC), haemoglobin, creatinine, estimated glomerular filtration rate (eGFR), erythrocyte sedimentation rate, 24-hour protein excretion, and ANCA), induction and maintenance therapy, disease complications, number of relapses, and data and cause of death. The total cumulative CYC dose was calculated taking into account all the CYC courses that patients received initially and during the follow-up.

The disease activity/severity at time of diagnosis and during the follow-up was estimated according to the Birmingham Vasculitis Activity Score (BVASv.3) (11,12), the 1996 Five Factor Score (1996 FFS) (13) and the 2009 FFS (14). BVASv.3 \geq 1 defined active disease (12). Uncontrolled vasculitis was defined as the occurrence of new manifestations or aggravation of manifestations already present despite treatment for the disease. Relapses were defined as recurrence of signs or new symptoms after an initial remission, severe enough to warrant a change in therapy. Acute renal failure was defined according to AKIN (15) as a rapid decline in renal filtration function manifested by an absolute increase in serum creatinine of \geq 0.3mg/dL or \geq 50% from baseline. Chronic kidney disease was defined as an eGFR<60mL/min/1.73m² in two consecutive analyses separated by at least 3 months. Renal disease was defined according to BVASv.3 (11,12,16) by the presence of haematuria \geq 10RBCs/hpf, proteinuria

Accepted Article

>0.2gr/24h, creatinine $\geq 125\mu\text{mol/L}$ (1.41mg/dL), hypertension, or a rise in serum creatinine >30% or fall in the eGFR >25%, not attributable to a medical problem other than vasculitis. Leukopenia was defined by the presence of WBC under 3.500cells/ μL in two successive blood tests. Pancytopenia was defined as a reduction in each type of peripheral blood cells (haemoglobin <10gr/dL, leukocytes <3.500cells/ μL , platelets <100.000/ μL). ANCA were determined by indirect immunofluorescence (IFI) and ELISA or chemiluminescence immunoassay according to the study period. Patients with positive ANCA by IFI but negative specificity were classified as ANCA negative. Major infections were defined as those that required hospitalization or intravenous antibiotics for at least for 24 hours. Sepsis and its source were individually evaluated in the statistical analysis. Opportunistic infection was defined as the infection caused by an organism (bacterial, viral, fungal or protozoan) with a low virulence capacity that take advantage of a weakened immune system causing disease when ordinarily could cause mild or no disease in immunocompetent host. Patients were treated according to the international recommendations (17) in each period.

Statistical analysis

Categorical variables were expressed as percentages, and continuous variables by mean \pm error standard of the mean (SEM) or median and interquartile range (IQR), according to their normal distribution based the Kolmogorov-Smirnov test. The Chi-squared test was used to compare categorical data between groups. Continuous data were analysed with the Student-T and ANOVA tests. Welch test was used when variances' differences were found using Levene's test. Associations of quantitative data were analyzed with the Student-t test and with the nonparametric test. Spearman's

Downloaded on April 18, 2024 from www.jrheum.org

Accepted Article

correlation coefficient was used to analyse relationship between quantitative variables. ROC curves were performed to examine the predictive value of each risk factor. Cut-off values were determined according to the Youden index (*see supplementary information*). For mortality analyses, independent variables that appeared to have statistical significance in the univariate analysis ($p < 0.05$) were included in the multivariate logistic regression model. The odds ratios (OR) and their 95% confidence interval (CI) obtained in the adjusted regression analysis were calculated. Cox regression model with infection as a time-dependent variable was used to analyse its influence on mortality. The effect was estimated as hazard ratio (HR), with 95%CI. Survival curves were constructed according to the Kaplan-Meier method and compared with log-rank test. A two-tailed $p < 0.05$ was considered statistically significant. Statistical analysis was performed using SPSS v.21.0 software.

Ethical approval:

The study was approved by the Institutional Review Board of our Hospital (PR(AG)289/2014) and performed in accordance with the ethical standards laid down in appropriate version of the Declaration of Helsinki. Due to the retrospective nature of the study informed consent was not required.

RESULTS

Epidemiological data

A total of 132 patients (48% men) with a median age of 57.5 (40.3-68.6) years at the time of diagnosis, were included in the study. AAV diagnosis was supported by histology in 115 (89%) cases, and by typical symptoms and clinical findings in conjunction with the presence of ANCA in the remaining cases. Overall, 51 (39%) patients were classified as having MPA, 52 (39%) GPA, and 29 (22%) EGPA. At the time of diagnosis ANCA test was positive in 112 (85%) patients, 39 (35%) PR3-ANCA and 73 (65%) MPO-ANCA. The median BVASv.3 at diagnosis was 16 (11.3-20.8), with no significant differences among groups. Statistical differences were detected in the 1996 and 2009 FFS between MPA and other AAV subsets ($p<0.05$) with higher values for MPA. Patients with MPA showed a mean creatinine value of $3.30\pm0.46\text{mg/dL}$ and a proteinuria of $1.38\pm0.2\text{gr/day}$, both significantly higher than in patients with GPA and EGPA ($p<0.001$). Nephrotic syndrome was only present in 9% of patients with no significant differences between MPA and GPA patients. No patients with EGPA showed nephrotic syndrome. The main demographic and clinical features, and laboratory data at diagnosis are summarized in Table 1.

Treatment

The treatment varied depending on the period of the disease diagnosis. After 2001, treatment was divided into two phases: an induction phase of 6 months followed by a maintenance phase of two years. All patients received oral corticosteroids (CS) as induction treatment. Additionally, pulses of methylprednisolone (MTP) were administered to 82/132 (62%) patients with severe manifestations, prior to oral CS therapy institution. Intravenous CYC was given to 55 (42%) patients and oral CYC to

56 (42%). Methotrexate (MTX) was given to 10 (8%) patients with early forms of GPA. Since 2001, according to the international recommendations (18) patients were progressively treated with CYC pulses instead of oral CYC, with a progressive reduction of oral CYC regimen resulting in a significant decrease of the total cumulative CYC dose (Figure 1).

As maintenance therapy, azathioprine (AZA) was given to 37/132 (28%) patients, mycophenolate mophetil (MMF) to 20 (15%) and MTX to 10 (8%). Trimetopim-sulfamethoxazol (TMP-SX) was administered to 81 (61%) patients as a prophylaxis of *Pneumocystis jirovecii* pneumonia (PjP) (800/160mg on alternate days) or adjunctive therapy on those patients who were nasal carriers of *Staphylococcus aureus* (800/160 mg twice daily). Biological therapy was used in 10 (8%) patients, mainly Rituximab, in most cases as a rescue therapy; one patient received Etanercept. Dialysis was needed in 25 (19%) patients.

Relapses

A total of 122 patients were eligible to be analysed, due to lack of complete data in 10 patients. Among them, 76/122 (62%) presented one or more relapses of the disease during the follow-up: 34/76 (45%) patients with GPA, 24 (31%) with MPA and 18 (24%) with EGPA. The mean relapses rate was 1.74 with a maximum of 17 relapses in a patient with GPA. The most relapsing subset of AAV was GPA with a mean relapse rate of 2.1 ± 0.4 per patient, followed by EGPA (2.0 ± 0.4) and MPA (1.2 ± 0.2). Patients with ENT involvement at the time of diagnosis presented more relapses than those without (2.23 ± 0.37 vs. 1.25 ± 0.19 , $p=0.02$). Patients with ANCA-PR3 suffered more

relapses than those with ANCA-MPO, although no statistical significance was reached (2.3 ± 0.5 vs. 1.4 ± 0.2 , $p=0.09$).

BVAS and FFS were not useful for differentiating relapsing from non-relapsing patients.

Infections

Five patients showed positive serology for HVC, with negative RNA. No cases for HBV anti-core antibody, surface antigen-HBV or HIV, were detected.

A total of 300 major infections occurred in 79/132 (60%) patients during the follow-up. Thirty-two (24%) patients suffered from two or more infections. Infections were more frequently located in the lower respiratory tract (64%), followed by the urinary (11%) and gastrointestinal (8%) tract, soft tissues (6%) and central nervous system (0.3%). Among patients with septicaemia (9%), 10 (39%) had a device-related infection (9 a catheter sepsis and 1 a pacemaker infection), 5 (20%) had urinary tract infections, 3 (12%) abdominal tract infections, and 2 (8%) respiratory tract infections. In 6 (23%) cases, the origin of bacteraemia was unknown.

Bacterial aetiology was suspected in 255 cases: 113 (44%) acute bronchitis, 62 (24%) pneumonia, 31 (12%) urinary tract infections, 26 (10%) sepsis/bacteraemia, and 23 (9%) gastrointestinal tract infections. The pathogen was identified in 142 cases. Viral infection was confirmed in 24 cases, fungal infection in 16, parasite infections in 3, and mycobacterial infections in other 3. Seventeen cases of herpes zoster were reported during the follow-up.

A total of 22 (7.3%) infections were considered opportunistic: 14 systemic mycosis, 3 CMV-pneumonitis, 3 pulmonary mycobacterial infections, and 2 Leishmaniasis. Ten

(45.5%) opportunistic infections took place during the first year of diagnosis. Twelve (54.5%) appeared while patients were under CYC treatment and 6 (27.3%) while patients were only under CS maintenance therapy. All infections-related data are summarized in the *Supplementary Table 3*.

No differences in the infection rate were observed between the different AAV subtypes. Bacterial infections were significantly related to a BVASv.3 >15 at the disease onset (OR 2.35, 95%CI 1.14-4.76, p=0.021), a total cumulative CYC dose >8.65gr (OR 2.67, 95%CI 1.15-4.82, p=0.008), dialysis requirement (OR 3.07, 95%CI 1.07-8.79, p=0.04), and development of leukopenia during the follow-up (OR 2.63, 95%CI 1.23-5.64, p=0.016).

Opportunistic infections were only significantly related to the presence of leukopenia during the follow-up (OR 4.31, 95%CI 1.43-12.98, p=0.006), and leukopenia was significantly related to the mean total cumulative CYC dose (43.3 ± 5.4 g vs. 14.1 ± 3.0 g, p<0.001) and to dialysis requirement (OR 5.5, 95%CI 2.00-15.09, p<0.001).

Outcome

A total of 44 (33%) deaths were registered: 25 (57%) MPA, 11 (25%) GPA and 8 (18%) EGPA. The mean time to death was 105 ± 14 months. Mortality was higher in patients with MPA than in those with GPA or EGPA (OR 2.97, 95%CI 1.41-6.29, p=0.005), and in patients with ANCA-MPO compared to those with ANCA-PR3 or negative ANCA (OR 2.24, 95%CI 1.05-4.79, p=0.042).

Regarding to the cause of death, an infectious process was present in 15 (34%) patients, a combination of active disease and infection in 7 (16%), a cardiovascular cause in 7 (16%), uncontrolled vasculitis in 6 (14%), respiratory failure in 4 (9%), and a neoplasm

Downloaded on April 18, 2024 from www.jrheum.org

in 3 (7%) patients. In 2 cases, the cause of death was unknown. Seven patients (16%) died at an early stage of the disease (≤ 12 months) while 37 died at a late stage (> 12 months). Major causes of death in each period are summarized in supplementary Table 4. Patients who suffered from a severe infection had an increased mortality from any cause (45% vs. 15.4%; HR 3.174, 95%IC 1.205 - 8.367; $p = 0.019$) (Figure 2). Table 2 shows the risk factors that were associated with death.

Survivors at the end of follow-up were younger than non-survivors (50.2 ± 1.8 vs. 64.0 ± 2.2 ; $p < 0.001$), had lower BVASv.3 (15.2 ± 0.7 vs. 18.4 ± 1 , $p = 0.011$), lower 2009 FFS (1.1 ± 0.1 vs. 1.8 ± 0.2 , $p < 0.001$) and lower creatinine levels (1.9 ± 0.2 vs. 2.6 ± 0.4 , $p = 0.032$) at diagnosis, and a lower rate of infections during the follow-up (1.3 ± 0.2 vs. 2.7 ± 0.4 , $p < 0.001$). Multivariable analysis showed age > 65 years and creatinine > 2 mg/dL at diagnosis, sepsis, opportunistic infections and a total cumulative CYC dose > 12.75 gr as independent factors related to mortality (Table 2).

DISCUSSION

Although the diagnosis and management of AAV has clearly improved over the last years, AAV mortality still remains significant, not only due to the disease activity but also to the treatment-related side effects. This study describes the largest cohort of patients from a single centre in Spain, focusing on the role that major infections play on all-cause mortality.

Epidemiological data and clinical features at diagnosis were similar in our patients to those described in the main European series (8,19–22). Major infections were registered in 60% of cases during the follow-up, a rate clearly superior to that reported in other larger cohorts (26 to 46 %) (21–24), probably due to the long-term follow-up in our cohort and the inclusion criteria (IV treatment for at least 24h). Similarly to described by other authors (10,25), the respiratory tract was the main source of infection (64% of cases), followed by the urinary tract, and sepsis due to vascular catheters used for intravenous treatment or renal replacement therapy. Bacterial infections were the most frequent cause of infections in our patients in line with other series (21,22). The percentage of opportunistic infections, mainly fungal pneumonia, was lower than in other studies (23,25). PjP was only reported in 2% of cases compared to other series (1–37.5%) (23,26). It was probably due to the routine use in our Centre of prophylactic treatment with TMP-SX in patients with sustained lymphocyte count $<1.00 \times 10^9$ cells/L and in all GPA patients, confirming its efficacy. After 2001, according to the international recommendations for AAV management (18), patients were progressively treated with CYC pulses instead of oral CYC, with a significant decrease of the total cumulative CYC dose, and a significant reduction of the infection rate, our data been similar to those previously reported in the literature (3,22).

Accepted Article

In our cohort, factors associated with major infections were BVASv.3>15 at diagnosis, total cumulative CYC dose >8.65gr, dialysis requirement and development of leukopenia during the follow-up. Our findings suggest that both the need for more intensive immunosuppressive regimens in patients with severe renal or systemic disease, and the need for longer treatments in patients with persistent active disease are related to a higher rate of infections. In this line, a greater percentage of infections has been described in patients treated with high total cumulative CYC dose (22,27), and also during the earliest phase of immunosuppressive treatment (10,21,24,28). Leukopenia, has also been reported in the literature as a surrogate marker of immunosuppression, especially related to an increased risk of sepsis (10,22,29). Similarly, renal dysfunction has been linked to an increased risk of infections through multiple pathways, including direct impairment of immune function (28). Moreover, in patients with renal failure, a decreased clearance of the immunosuppressant drugs could lead to an increased drug exposure and a higher toxicity (30). Finally, the more active disease the more extensive organ damage, which could contribute to permanent long-term sequel such as lung cavities, which may predispose to infections.

Regarding opportunistic infections, the only factor significantly related to its development in the present study was the presence of leukopenia during the follow-up. Leukopenia was more frequent in patients with high total cumulative CYC dose and in those who required renal replacement therapy, similar to bacterial infections. Noteworthy, almost 50% of all opportunistic infections took place in the first year of diagnosis. Moreover, up to 82% of all cases occurred while patients were under immunosuppressant drugs therapy or CS treatment, although 18% appeared in patients who were not receiving immunosuppressant drugs at the time of infection, but who had received a high immunosuppressant load. Leukopenia, due to immunosuppressant

therapy, has already been reported as a risk factor for opportunistic infections in other studies (10,22,29).

In our series, mortality was clearly related to the disease activity and to the presence of major infections, and the strong association between both hampered elucidations of which of the two causes was the main factor in some cases. At least, in 34% of all deceased patients, infection was considered the main factor, and a contributing factor in 16% of the remaining patients. Patients who suffered from a major infection showed a higher mortality rate from any cause than those who never suffered from infections (45% vs. 15.4%). Multivariate analysis identified sepsis (OR 13.06, 95%CI 1.49 - 114.03) and opportunistic infections (OR 7.08, 95%CI 1.57 - 40.18) as independent factors related to death.

Other factors related to death in our series were age >65 years at diagnosis, severe renal failure and total cumulative CYC dose >12.75gr. Age older than 60 years at the time of AAV diagnosis has been previously identified as a poor prognostic factor (8,9,20,22,29,31–34), probably due to a greater comorbidity and an increased risk of adverse events and drugs intolerance. Decline of eGFR (8,9,25,29,33–38) and renal replacement therapy requirement (33) have been both related to a poor outcome due to a higher risk of infections and treatment toxicity, in line with our results. Finally, morbidity related to high total cumulative CYC dose has been extensively described (22). Not significant relationship between BVASv.3 at diagnosis and disease outcome was found in our study, although it has been described by other authors, suggesting a link between the disease severity at baseline and mortality (8,22,34). Regarding to the AAV subtype, MPA was found to have the worse prognosis compared to the other subsets (8,9,39) probably due to the more severe renal involvement and the older age of patients at the disease diagnosis (8) as previously suggested. ENT involvement was

Downloaded on April 18, 2024 from www.jrheum.org

found to be a protective factor in agreement with several studies (20,22,32,36), probably due to its predominance in limited or granulomatous forms of GPA which tend to show less severe renal involvement, mild lung involvement and better outcome compared to the vasculitic forms (32,40).

The 1-year and 5-years survival rates in our cohort were 94.7% and 85.6%, respectively, quite similar to those reported in by other authors (4,8,20,36). The early mortality (<12months) accounted for 16% of all deaths, and was related to a combination of disease activity/infections in up to 57% of all the deceased patients. The late mortality was also related to infections and disease activity, with a 59% contribution in all the deceased patients. However, a significant increase of cardiovascular causes was observed at this stage, being the main factor in up to 16% of deaths. This could reflect an increased burden on cardiovascular risk associated to inflammation and treatments, as suggested in recent studies (8,9,41). Malignancies also arose as a late cause of death, in 8% of cases. An increased risk of neoplasms, specially for leukaemia, urinary bladder and skin malignancies, has been described in patients with AAV (8,42,43).

The present study has several limitations derived from the retrospective nature of the analysis due to the inevitable loss of information, and the possible underestimation of the activity scores. Likewise, the primary cause of death was difficult to elucidate in some cases due to the concomitant existence of multiple factors such as disease activity and infection. However, to our knowledge, this is the largest single-centre study from a Spanish cohort, compiling detailed information about major infections in patients with AAV and its influence on the patient's outcome.

In summary, although active disease still remains one of the main causes of death in patients with AAV, especially in the first months of follow-up, infectious events play a key role in the prognosis throughout the disease course. Therefore, it is important to

Downloaded on April 18, 2024 from www.jrheum.org

Accepted Article

identify predisposing factors such as intensive immunosuppressant treatment, severe renal dysfunction and leukopenia, and stratify treatment according to the disease severity, seeking a balance between the risk of relapses and/or persistent activity and the risk of unwanted treatment side effects. New therapies may help reducing the total cumulative CYC dose and the total corticosteroid dosage, both clearly related to infectious events. Strategies for preventing infection by the most common pathogens (removal of non-essential intravascular catheters placement, etc.) might also help to reduce the incidence of severe infections. Prophylaxis with TMP-SX must be used in order to prevent PjP in immunosuppressed patients.

ACKNOWLEDGEMENTS

All authors declare no conflicts of interest.

REFERENCES

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013;65:1–11.
2. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. *Lancet*. 2006;368:404–18.
3. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med*. 1983;98:76–85.
4. Kallenberg CGM. The diagnosis and classification of microscopic polyangiitis. *J Autoimmun*. 2014;48–49:90–3.
5. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. *Am J Pathol*. 1951;27:277–301.
6. Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda Vriesman P, Cohen Tervaert JW, et al. Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. *Nephrol Dial Transplant*. Oxford University Press. 2013;28:373–9.
7. Schonermarck U, Grahovac M, Sardy M, Dolch M, Wollenberg A. Fulminant primary manifestations of Wegener's granulomatosis might not be pauci-immune. *Clin Kidney J*. 2010;3:567–9.
8. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis*. 2011;70:488–94.
9. Lai Q-y., Ma T-T, Li Z-y., Chang D-y., Zhao M-H, Chen M. Predictors for Mortality in Patients with Antineutrophil Cytoplasmic Autoantibody-associated Vasculitis: A Study of 398 Chinese Patients. *J Rheumatol*. 2014;41:1849–55.
10. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. *Ann Rheum Dis*. 2010;69:1036–43.
11. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. *QJM*. 1994;87:671–8.
12. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). *Ann Rheum Dis*.

Downloaded on April 18, 2024 from www.jrheum.org

- 2009;68:1827–32.
13. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)*. 1996;75:17–28.
 14. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. *Medicine (Baltimore)*. 2011;90:19–27.
 15. Mehta RL, Kellum JA, Shah S V, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care*. 2007;11:R31.
 16. Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). *Arthritis Rheum*. 2001;44:912–20.
 17. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016;75:1583–94.
 18. Jayne D. Evidence-based treatment of systemic vasculitis. *Rheumatology (Oxford)*. 2000;39:585–95.
 19. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. *Arthritis Rheum*. 2013;65:270–81.
 20. Bligny D, Mahr A, Toumelin P Le, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. *Arthritis Rheum*. 2004;51:83–91.
 21. Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. *Ann Rheum Dis*. 2009;68:658–63.
 22. Solans-Laqué R, Fraile G, Rodriguez-carballeira M, Caminal L, Castillo MJ, Rios JJ, et al. Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides. Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. *Medicine (Baltimore)*. 2017;96:8(e6083).

Downloaded on April 18, 2024 from www.jrheum.org


- Accepted Article
23. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. *Clin Rheumatol*. 2007;26:663–70.
 24. Morton M, Edmonds S, Doherty AM, Dhaygude A, Helbert M, Venning M. Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement. *Rheumatol Int*. 2012;32:3373–82.
 25. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients. *Rheumatology (Oxford)*. 2005;44:495–501.
 26. Jarrousse B, Guillevin L, Bindi P, Hachulla E, Leclerc P, Gilson B, et al. Increased risk of *Pneumocystis carinii* pneumonia in patients with Wegener's granulomatosis. *Clin Exp Rheumatol*. 1993;11:615–21.
 27. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. *Arthritis Rheum*. 1997;40:2187–98.
 28. Mohammad AJ, Segelmark M, Smith R, Englund M, Nilsson J-Å, Westman K, et al. Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. *J Rheumatol*. 2017;44:1468–75.
 29. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. *Am J Kidney Dis*. 2003;41:776–84.
 30. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. *Kidney Int*. 2002;61:1495–501.
 31. Vassallo M, Shepherd RJ, Iqbal P, Feehally I. Age-related variations in presentation and outcome in Wegener's granulomatosis. *J R Coll Physicians Lond*. 1997;31:396–400.
 32. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. *Rheumatology*. 2001;40:492–8.
 33. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. *Rheumatology*. 2002;41:572–81.
 34. Corral-Gudino L, Borao-Cengotita-Bengoa M, del Pino-Montes J, Lerma-Márquez JL.

- Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. *Rheumatology*. 2011;50:1414–23.
35. Reinhold-Keller E, Beuge N, Latza U, De Groot K, Rudert H, Nölle B, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. *Arthritis Rheum*. 2000;43:1021-32.
 36. Takala J, Kautiainen H, Leirisalo-Repo M. Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981–2000. *Scand J Rheumatol*. 2010;39:71–6.
 37. Eriksson P, Jacobsson L, Lindell Å, Nilsson J-Å, Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. *J Intern Med*. 2009;265:496–506.
 38. Rhee RL, Hogan SL, Poulton CJ, McGregor JAG, Richard Landis J, Falk RJ, et al. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. *Arthritis Rheumatol*. 2016;68:1711–20.
 39. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. *Ann Rheum Dis*. 2008;67:1004–10.
 40. Carrington CB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener's type. *Am J Med*. 1966;41:497–527.
 41. Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. *Arthritis Rheum*. 2009;60:3493–500.
 42. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. *Ann Intern Med*. 1996;124:477–84.
 43. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. *Int J cancer*. 2002;100:82–5.

FIGURE LEGENDS

Figure 1. Percentage of patients treated with oral or intravenous CYC and total cumulative dose of CYC according to the year of diagnosis. CYC = Cyclophosphamide; IV = Intravenous.

Figure 2: Long-term Survival according to major infections. Kaplan–Meier survival analysis (n=132) comparing patients with and without major infections.






Table 1: Demographic, clinical manifestations and laboratory data at AAV diagnosis

	Total (n = 132) n (%)	GPA (n=51) n (%)	MPA (n=52) n (%)	EGPA (n=29) n (%)	P
Epidemiological data					
<i>Gender (male/female)</i>	63/69	27/24	25/27	11/18	0.043
<i>Age at diagnosis (year)</i>	57.5 (40.3-68.6)	38.0 (32.0-56.0)	67.5 (58.0-75.7)	55.0 (49.0-67.5)	<0.001
<i>ANCA positive</i>	112 (85%)	42 (82%)	51 (98%)	19 (65%)	<0.001
<i>PR3-ANCA</i>	39 (30%)	36 (71%)	2 (4%)	1 (3%)	<0.001
<i>MPO-ANCA</i>	73 (55%)	6 (12%)	49 (94%)	18 (62%)	<0.001
<i>BVASv.3</i>	16 (9-22)	16.1 ± 1.0	17.1 ± 0.9	15.2 ± 1.1	0.440
<i>FFS 1996</i>	0 (0-1)	0 (0-1)	1 (0-2)	0 (0-0)	<0.05
<i>FFS 2009</i>	1 (0-2)	1 (0-1)	2 (2-3)	1 (0-1)	<0.001
Clinical manifestations					
<i>Toxic syndrome</i>	101 (77%)	35 (69%)	44 (85%)	22 (76%)	0.172
<i>Fever</i>	84 (64%)	28 (55%)	34 (65%)	22 (76%)	0.188
<i>ENT involvement</i>	62 (47%)	42 (84%)	2 (4%)	18 (62%)	<0,05
<i>Nasal crusting</i>	28 (21%)	25 (49%)	0 (0%)	3 (10%)	<0,001
<i>Septal perforation</i>	2 (2%)	2 (4%)	0 (0%)	0 (0%)	0.316
<i>Otitis media</i>	24 (18%)	19 (37%)	0 (0%)	5 (17%)	<0,05
<i>Paranasal sinuses involve.</i>	44 (33%)	27 (53%)	2 (4%)	15 (52%)	<0,001
<i>Subglottic stenosis</i>	5 (4%)	5 (10%)	0 (0%)	0 (0%)	0,06
<i>Pulmonary infiltrates</i>	60 (45%)	16 (31%)	24 (46%)	20 (69%)	0.003
<i>Lung Nodules</i>	27 (20%)	23 (45%)	2 (4%)	2 (7%)	<0,001
<i>Alveolar haemorrhage</i>	24 (18%)	8 (16%)	15 (29%)	1 (3%)	0'013
<i>Acute renal Failure</i>	61 (46%)	20 (39%)	40 (77%)	1 (3%)	<0,001
<i>Renopulmonary syndrome</i>	20 (15%)	7 (14%)	14 (27%)	0 (0%)	0,004
<i>Nephrotic syndrome</i>	12 (9%)	5 (10%)	7 (14%)	0 (0%)	0.126
<i>Neurologic affection</i>	50 (38%)	8 (16%)	20 (38%)	22 (76%)	<0,001
<i>Peripheral neuropathy</i>	11 (8%)	0 (0%)	8 (15%)	3 (10%)	0.026
<i>Mononeuritis multiplex</i>	39 (30%)	8 (16%)	12 (23%)	19 (66%)	<0,001
<i>Central Nervous system</i>	12 (9%)	9 (18%)	2 (4%)	1 (3%)	<0.05
<i>Stroke</i>	7 (5%)	5 (10%)	2 (4%)	0 (0%)	0.184
<i>Aseptic Meningitis</i>	5 (4%)	5 (10%)	0 (0%)	0 (0%)	0.026
<i>Optical neuritis</i>	1 (1%)	0 (0%)	0 (0%)	1 (3%)	ns
<i>Myocarditis</i>	3 (2%)	0 (0%)	0 (0%)	3 (10%)	ns
<i>Pericarditis</i>	3 (2%)	2 (4%)	1 (2%)	0 (0%)	ns
<i>Intestinal ischemia</i>					
<i>Ulcers</i>	8 (6%)	5 (10%)	2 (4%)	1 (3%)	ns
<i>Perforation</i>	2 (2%)	2 (4%)	0 (0%)	0 (0%)	ns
Laboratory data					
<i>Haemoglobine (g/dL)</i>	10.7 ± 0.2	11.2 ± 0.3	9,6 ± 0.2	12.2 ± 0.3	<0,001
<i>Leukocytes (x10E9/L)</i>	12.96 ± 5.62	11.87 ± 8.59	11.81 ± 5.91	16.94 ± 1.59	0,002
<i>ESR (mmh⁻¹)</i>	82 ± 3	82 ± 5	91 ± 3	64 ± 5	0,016
<i>Creatinine (mg/dL)</i>	2.11 ± 0.22	1.62 ± 0.22	3,30 ± 0.46	0.85 ± 0.03	<0,001
<i>Proteinuria (mg/day)</i>	925 ± 131	874 ± 218	1379 ± 234	179 ± 29	<0,001

ANCA = Antineutrophil cytoplasmic antibodies; BVAS = Birmingham Vasculitis Activity Score; EGPA = Eosinophilic granulomatosis with polyangiitis; ENT = Ear nose throat; ESR = Erythrocyte sedimentation rate; FFS = Five Factor Score; GPA = Granulomatosis with polyangiitis; MPA = Microscopic polyangiitis; MPO = myeloperoxidase; PR3 = proteinase-3.

Table 2: Factors associated with an increased mortality

	Univariate Analysis					Multivariate Analysis		
Factor	Non-survivors (%)	Survivors (%)	OR	95%CI	P	OR	95%CI	P
Age at diagnosis >65 years	50.0	25.0	3.00	1.40-6.43	0.006	6.78	1.44-31.99	0.016
MPA	56.8	30.6	2.97	1.41-6.29	0.005			
BVASv.3 > 15	72.7	50.0	2.67	1.22-5.84	0.015			
ENT affection at diagnosis	31.8	54.5	0.39	0.18-0.83	0.016			
Renal failure at diagnosis	59.1	39.7	2.18	1.05-4.57	0.043			
Necrotizing Glomerulonephritis	51.2	28.4	2.64	1.24-5.62	0.013			
Bacterial Infections	81.8	50.0	4.50	1.88-10.77	0.001			
Pneumonia	45.4	22.7	2.83	1.30-6.15	0.009			
Urinary tract infection	31.8	10.2	4.09	1.60-10.45	0.006			
Sepsis	43.2	4.5	15.95	4.96-51.27	<0.001	13.06	1.49-114.03	0.020
Opportunistic infections	27.3	9.1	3.75	1.40-10.03	0.009	7.08	1.25-40.18	0.027
Leukopenia	62.8	32.1	3.56	1.65-7.69	0.001			
Pancytopenia	16.3	1.3	15.17	1.78-127.9	<0.001			
Creatinine > 2mg/dL	47.7	19.3	3.81	1.72-8.43	0.001	14.86	1.44-153.58	0.024
MPO-ANCA	68.1	48.9	2.24	1.05-4.79	0.042			
Accumulative dosage of CYC >12,75gr	63.6	36.4	3.06	1.44-6.50	0.005	7.70	1.57-37.77	0.012
TMP-SX	48.8	69.0	0.43	0.20-0.91	0.034			
Dialysis	39.5	9.1	6.54	2.53-16.90	<0.001			
ANCA = Antineutrophil cytoplasmic antibodies; AZA = Azathioprine; BVAS = Birmingham Vasculitis Activity Score; CI = Confidence interval; CYC = Cyclophosphamide; ENT = Ear nose throat; MPA = Microscopic polyangiitis; OR = Odds ratio; TMP-SX = Trimethoprim-Sulfamethoxazol.								